PT Soho Global Health Tbk

SOHO

Overview

SOHO Overview

PT Soho Global Health Tbk is an Indonesia-based company. The Company operates in the healthcare sector. The Company operates through five segments: Distribution, Professional product, Consumer health, Alliance, and Others. Its brands include Curcuma Plus, Curcuma Plus Milk, Imboost, Fitkom, Diapet, Laxing, Lelap, Asthma Soho and Sohobion. Curcuma Plus is a kid’s multivitamin that contains curcuma and fish oil. Curcuma Plus Milk is a growing up milk for kids. Imboost is a supplement that supports immune system. Fitkom offers kids multivitamins in gummy and tablet format. Diapet is an anti-diarrheal medicine. Laxing is a medicine for healthy digestion and bowel movement. Lelap is a medicine to alleviate sleep disorders. Asthma Soho is an asthma remedy. Sohobion is a neurotropic vitamin supplement to maintain neurological health. The Company's product portfolio ranged from wound care, hospital general care, surgery, orthopedics, and in-vitro diagnostics.

51015ValueCompetitiveFutureFinancialsDividend
Exchange
Indonesia Stock Exchange

Symbol: SOHO

Watchlist
Market Cap.
IDR 6.32Trillion

~$395.38M USD

Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Sector
Healthcare

Valuation

SOHO Valuation Metrics

498

IDR
0.0%

Closing Price on 2024-05-22

Price to Equity

17.02

P/E

At 17.02x P/E TTM, SOHO.JK is trading at a premium to its peers in the Pharmaceuticals & Health Care Research sector (avg 10.9x).

Price to Book

2.63

P/B

At 2.63x P/B TTM, SOHO.JK is trading at a premium to its peers in the Pharmaceuticals & Health Care Research sector (avg 1.7x).

Price to Sales

0.77

P/S

At 0.77x P/S TTM, SOHO.JK is trading in line with its peers in the Pharmaceuticals & Health Care Research sector.

Valuing PT Soho Global Health Tbk based on its trailing twelve months (TTM) valuation metrics against its peers in the Pharmaceuticals & Health Care Research sector

Historical Price to Earnings

Other Valuation Metrics

Valuing PT Soho Global Health Tbk relative to other stocks in the Pharmaceuticals & Health Care Research sector

Price/Cash Flow
29.94x
Price/Forward Earnings
-
Enterprise Value/Revenue
0.66x
Enterprise Value/EBITDA
10.57x
PEG Ratio
0.36x

Analyst Ratings

No analyst ratings available yet.

Valuation Recap of SOHO stock
WeightNotesScore
High
The P/E ratio is calculated by dividing the market price of a company's stock by its earnings per share (EPS). It is a key tool for investors and analysts to assess whether a stock is overvalued, undervalued, or fairly valued. A P/E ratio of 17.02x is above the ID market average of 8.70x and is trading at a premium to peers in the Pharmaceuticals & Health Care Research sector (10.87x).

High
The P/B ratio is calculated by dividing the market price of a company's stock by its book value per share (BVPS). It measures the company's stock value relative to its assets minus liabilities. A P/B ratio of 2.63x is above the peers average of 1.74x in the Pharmaceuticals & Health Care Research sector.

Medium
The P/S ratio is calculated by dividing the market price of a company's stock by its sales per share. It measures the company's stock value relative to its sales. A P/S ratio of 0.77x is similar to the peers average of 0.84x in the Pharmaceuticals & Health Care Research sector. When considered alongside the Forward Price/Earnings ratio, they serve to illustrate investors' expectations of SOHO's valuation relative to its current sales and future earnings growth.

Low
The Price/Cash Flow ratio (P/CF) is calculated by dividing the market price of a company's stock by its cash flow per share. It measures the company's stock value relative to its cash flow, and is sometimes said to be a more objective measure of a company's value because cash flows cannot be manipulated as easily as earnings, which considers non-cash items such as depreciation and amortization. SOHO's P/CF ratio of 29.94x is considered a relatively high ratio by analysts.

Low
The Enterprise Value/Revenue ratio (EV/R) is calculated by dividing the enterprise value of a company by its revenue. It measures the company's enterprise value relative to its revenue. It is an indicator of how much it costs to buy the company's revenue; the lower the ratio, the cheaper the company's revenue. SOHO's EV/R ratio of 0.66x is considered extremely underpriced by the market The average EV/R ratio for the Pharmaceuticals & Health Care Research sector is 1.41x.

Peers

SOHO Peers and Comparison

Peer Companies

Supertype Fuzzy Search
SymbolCompany Name
Market Cap
(in Trillion IDR)
Total Assets
(in Trillion IDR)
Total Revenue
(in Trillion IDR)
Profit and Loss
(in Trillion IDR)
P/E
P/B
KLBFKalbe Farma Tbk72.16T27.06T 30.45T 2.77T 26.083.37
MIKAPT Mitra Keluarga Karyasehat Tbk.42.97T7.34T 4.26T 0.92T 46.917.38
SILOPT Siloam International Hospitals Tbk.32.72T10.98T 11.19T 1.21T 27.014.13
SIDOPT Industri Jamu Dan Farmasi Sido Muncul Tbk21.45T3.89T 3.57T 0.95T 22.566.34
SRAJSejahteraraya Anugrahjaya Tbk20.58T5.61T 2.50T -0.04T -534.7211.09
HEALPT Medikaloka Hermina Tbk.19.88T8.80T 5.78T 0.44T 45.455.14
PRAYPT Famon Awal Bros Sedaya Tbk9.35T4.70T 1.84T 0.22T 43.113.34
TSPCTempo Scan Pacific Tbk9.16T11.32T 13.12T 1.18T 7.781.19
SOHOPT Soho Global Health Tbk6.32T4.75T 8.20T 0.37T 17.022.63
OMEDPT Jayamas Medica Industri Tbk5.47T2.58T 1.74T 0.26T 21.072.46
Competitiveness Recap of SOHO stock
WeightNotesScore
High
At a market cap of IDR 6,320.47 billion, SOHO.JK ranks 9 in Market Cap out of 10 companies in the Healthcare sector.

High
At a PE of 17.02, SOHO.JK ranks 8 out of 10 companies in the Healthcare sector for P/E value. The average PE is -27.77 (unadjusted). A high P/E ratio often indicates higher growth expectation, or other qualitative factors that led investors to believe that the company has a defensible competitive advantage compared to its peers in Healthcare. In this regard, it trails behind sector leaders such as PT Mitra Keluarga Karyasehat Tbk. (46.91) in the Healthcare sector.

Medium
At a PE of 17.02, SOHO.JK is trading at a higher PE than that of its subsector peers in Pharmaceuticals & Health Care Research (median of 10.87). false

Medium
At a revenue of IDR 8.20 trillion, SOHO.JK ranks 4 in Revenue out of 10 companies in the Healthcare sector.

Medium
At a profit of IDR 0.37 trillion, SOHO.JK ranks 7 in Profit out of 10 companies in the Healthcare sector.

Future

Future Growth of SOHO

Growth Forecasts

No data available

Sector Benchmark

Pharmaceuticals & Health Care Research companies in Indonesia are growing at a projected rate of 14.72% against the IDX average of +13.8%.

Pharmaceuticals & Health Care Research sector overview
No data is available for SOHO at the moment.
Future growth prospect of SOHO
WeightNotesScore
High
SOHO's projected growth rate of 14.72% is above the ID market average of 13.80%.

High
The Pharmaceuticals & Health Care Research sub-sector is projected to grow revenue by 15.79% in 2025. This number is higher than the previous year 2024's growth rate of -5.79%. This bodes well for SOHO's revenue growth prospects in the next 2 years.

Medium
The Pharmaceuticals & Health Care Research sub-sector is projected to increase earnings by 24.87% in 2025. This number is higher than the previous year 2024's EPS growth of 0.00%. This bodes well for SOHO's earnings growth prospects in the next 2 years.

Medium
SOHO and its peers in the Pharmaceuticals & Health Care Research sub-sector belongs to the Healthcare sector. Companies in the Healthcare sector are projected to have a fruitful year heading into 2025. Specifically, earnings are projected to increase by 22.78% in 2025 while revenue growth is projected to increase by 20.04%. These macroeconomic trends will likely be a tailwind for SOHO's earnings growth prospects in the next 2 years.

Loading...
Loading...

Management

Executive Management

President Director

Rogelio Paulino Jr. Castillo La O15.2 years
Piero Brambati
Director
Yuliana
Director
Henryk Klakurka
Director
Tan Ting Luen
Director
Wonbae Lee
Director
NamePositionShares%
No data is available for SOHO at the moment.
Expressed in millions IDR, unless otherwise stated

Ownership

SOHO Ownership

Others
4.09%
Insiders
95.91%
Institutions
0%
NameNumber of SharesOwnership (%)Value
Tiberias 96 Pty Ltd4,812,370,31037.922,396.56B
Medisia Investment Holdings Pte. Ltd.2,851,733,00022.471,420.16B
Cascade Creek Pty Ltd1,537,362,00012.11765.61B
Fraburg Pty Limited1,202,423,9109.47598.81B
Tan Giok Nio1,143,986,1709.01569.71B
Prysselius Limited624,206,7004.92310.85B
Public (Scripless)519,600,3004.09258.76B
No data is available for SOHO at the moment.